About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a company based in Carlsbad (United States) founded in 1990. It operates as a HealthTech. Lineage Cell Therapeutics has raised $45.8 million across 22 funding rounds from investors including Juvenescence, State of California and HHS. The company has 77 employees as of December 31, 2024. Lineage Cell Therapeutics has completed 4 acquisitions, including Asterias Biotherapeutics, Canadian Neighbor Pharmacy and Glycosan. Lineage Cell Therapeutics offers products and services including OpRegen and OPC1. Lineage Cell Therapeutics operates in a competitive market with competitors including Revance Therapeutics, Dermavant, Remegen, Sol-Gel Technologies and SkinMedica, among others.
- Headquarter Carlsbad, United States
- Employees 77 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lineage Cell Therapeutics, Inc.
-
Annual Revenue
$9.5 M6.19as on Dec 31, 2024
-
Net Profit
$-18.61 M13.39as on Dec 31, 2024
-
EBITDA
$-20.87 M13.19as on Dec 31, 2024
-
Total Equity Funding
$45.8 M (USD)
in 22 rounds
-
Latest Funding Round
-
Investors
Juvenescence
& 3 more
-
Employee Count
77
as on Dec 31, 2024
-
Investments & Acquisitions
Asterias Biotherapeutics
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lineage Cell Therapeutics
Lineage Cell Therapeutics is a publicly listed company on the AMEX with ticker symbol LCTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lineage Cell Therapeutics
Lineage Cell Therapeutics offers a comprehensive portfolio of products and services, including OpRegen and OPC1. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cell therapy developed for dry AMD treatment in patients.
Cell therapy designed for spinal cord injury recovery.
Funding Insights of Lineage Cell Therapeutics
Lineage Cell Therapeutics has successfully raised a total of $45.8M across 22 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 22
- Last Round Last Round
-
First Round
First Round
(21 May 2009)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Grant - Lineage Cell Therapeutics | Valuation |
investors |
|
| May, 2023 | Amount | Grant - Lineage Cell Therapeutics | Valuation |
investors |
|
| Sep, 2020 | Amount | Grant - Lineage Cell Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lineage Cell Therapeutics
Lineage Cell Therapeutics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Juvenescence, State of California and HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Access to government programs and development services is provided.
|
Founded Year | Domain | Location | |
|
Business development in Israel is supported by a government organization.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lineage Cell Therapeutics
Lineage Cell Therapeutics has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Asterias Biotherapeutics, Canadian Neighbor Pharmacy and Glycosan. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of cell therapy programs to treat cancer and neurological diseases
|
2013 | ||||
|
Canadian Neighbor Pharmacy is engaged in online distribution of generic medications.
|
2012 | ||||
|
Biocompatible hydrogels mimicking extracellular matrix are developed for tissue engineering.
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Lineage Cell Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lineage Cell Therapeutics Comparisons
Competitors of Lineage Cell Therapeutics
Lineage Cell Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Dermavant, Remegen, Sol-Gel Technologies and SkinMedica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| domain | founded_year | HQ Location |
Skin care products are developed and manufactured by SkinMedica.
|
|
| domain | founded_year | HQ Location |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lineage Cell Therapeutics
Frequently Asked Questions about Lineage Cell Therapeutics
When was Lineage Cell Therapeutics founded?
Lineage Cell Therapeutics was founded in 1990 and raised its 1st funding round 19 years after it was founded.
Where is Lineage Cell Therapeutics located?
Lineage Cell Therapeutics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Who is the current CEO of Lineage Cell Therapeutics?
Brian Culley is the current CEO of Lineage Cell Therapeutics.
Is Lineage Cell Therapeutics a funded company?
Lineage Cell Therapeutics is a funded company, having raised a total of $45.8M across 22 funding rounds to date. The company's 1st funding round was a Grant of $576.44K, raised on May 21, 2009.
How many employees does Lineage Cell Therapeutics have?
As of Dec 31, 2024, the latest employee count at Lineage Cell Therapeutics is 77.
What is the annual revenue of Lineage Cell Therapeutics?
Annual revenue of Lineage Cell Therapeutics is $9.5M as on Dec 31, 2024.
What does Lineage Cell Therapeutics do?
Lineage Cell Therapeutics is engaged in the development of novel allogeneic cell therapies targeting serious neurological and ophthalmic conditions. The company utilizes a proprietary cell-based technology platform for designing, manufacturing, and testing specialized human cells. These cells are intended to replace or support dysfunctional cells caused by degenerative diseases, aging, or traumatic injuries. Programs such as OpRegen for dry AMD and OPC1 for spinal cord injury are advanced internally or with strategic partners like Genentech to enhance therapeutic value and success probability in the healthcare sector.
Who are the top competitors of Lineage Cell Therapeutics?
Lineage Cell Therapeutics's top competitors include Revance Therapeutics, Remegen and Dermavant.
What products or services does Lineage Cell Therapeutics offer?
Lineage Cell Therapeutics offers OpRegen and OPC1.
Is Lineage Cell Therapeutics publicly traded?
Yes, Lineage Cell Therapeutics is publicly traded on AMEX under the ticker symbol LCTX.
How many acquisitions has Lineage Cell Therapeutics made?
Lineage Cell Therapeutics has made 4 acquisitions, including Asterias Biotherapeutics, Canadian Neighbor Pharmacy, and Glycosan.
Who are Lineage Cell Therapeutics's investors?
Lineage Cell Therapeutics has 4 investors. Key investors include Juvenescence, State of California, HHS, and Israel Innovation Authority.
What is Lineage Cell Therapeutics's ticker symbol?
The ticker symbol of Lineage Cell Therapeutics is LCTX on AMEX.